 |
|
|
|
|
|
|
|
|
|
|
|
|
Sponsored and organized by:
WHERE INNOVATIVE LIFE SCIENCE COMPANIES
MEET
INVESTORS
//
Next Edition
March 1st-2nd 2022//
Euro-Swiss Technopole
//Archamps//France
| Who
should attend and Why? |
Who should attend
BioData is the yearly Swiss symposium where leaders of the Swiss and international biopharmaceutical and medical technology industry meet investors. The programme is designed to inform venture capitalists, financial analysts and fund managers responsible for asset allocation of the current issues facing the industry (see the list of financial institutions below).
The programme at a glance
The ninth edition of BioData will include keynote lectures and panel discussions with a strong focus on medical technology companies and discuss some of the factors behind the success of this industry sector. The summary programme will be available here.
Why should you participate?
• Learn about recent industry trends that will influence your investment or business partnering decisions
• Discover exciting new opportunities for discerning investments or business-to-business partnerships in the biopharmaceutical and medical technology sectors
• Network with CEOs and other senior level executives from leading pharmaceutical and biotechnology companies
• Take part in one-on-one meetings with representatives from Swiss and international companies
• Make key business contacts in the Geneva area, one of the leading centres of research excellence in mainland Europe
BioData brings together:
• Decision makers, CEOs and other senior level executives from
- Leading pharmaceutical companies
- Biotechnology companies at the cutting edge of new technologies
- Medical technology companies
- Other major high tech industries
• Institutional investors such as fund managers and analysts
• Opinion leaders with a clear vision of the major issues facing the life science industry from a scientific, ethical and economic perspective
• Financial and business media
List of Financial Institutions having participated in BioData
|
3i Gestion Active Advisors Activgest Adamant Biomedical Investments Affentrager & Associates AFFIX Corporate Finance AGF Private Equity Aisling Capital Alexion Ventures AlpInvest Partners N.V Alta Berkeley Amorcage Rhône Alpes Apax Partners Aravis Partners Atlas Ventures Auriga Partners Avance, Basel GmbH AXA Private Equity Banco del Gottardo Banexi Ventures Partners Bank Bellevue Asset Mgt Bank Julius Baer Bank Leu Bank Sal. Oppenheim & Cie Bank Sarasin Bank Vontobel Banque Cantonale de Genève Banque Cantonale Vaudoise Banque Faisal Banque Nationale Suisse BB Biotech Ventures Berna Venture BioAlps BioArk / CimArk BioAssociés Sarl Biobank Technology Ventures L BioGestion-Fonds Bioam Biomed Invest Biosafe BNP Paribas Bordier & Cie Breslin Biotech Brilleon Capital Bryan, Garnier & Co BSI BT&T Group BZ Bank Canaccord Capital Capital Group Companies CDC Entreprises FP Gestion |
CDC Entreprises Innovation CITCO Citigroup Clariden CNCE Coges Creadvise Crédit Agricole Cheuvreux Credit Agricole Private Equity Crédit Lyonnais Crédit Suisse Cukierman & Co Life Sciences Daiwa Securities De Pury Pictet Turrettini & Cie Defi Gestion Deka Investment Developement Economic Western Switzerland Dimension Corporate Finance Dresdner Bank Eclosion Edmond de Rotshild Investment Partners EFG Bank Endeavours Equinet ERAI E-Synergy Euronext European Ventures Partners Ferrier Lullin & Cie Fonds Européen d'Investissement Freelancer Gedefi Asset Management SA Genevest Consulting group Global Biomedical Partners Global Life Science Ventures Goldmann Sachs HBM BioVentures HealthCap Helvea Himalaya Capital Partners Index Ventures Inventages Venture Capital Invest in Western France JP Morgan Landsbanki Kepler NeoMed New England Partners NMT
|
Lombard Odier Darier Hentsch Matignon Investissement et Gestion MDL Finance Medinsight Kepler Equities Merrill Lynch Morgan Stanley Nipralabs Investment Management Nomura Novartis Venture Fund NYSE Euronext NZB Neue Zürcher Bank Omega Advisors Orbimed Advisors Oxford BioScience Partners Panmure Gordon Pantheon Ventures Paul Capital Partners Pictet & Cie PricewaterhouseCoopers Private Bank Switzerland Renaissance Robert Frazer Finance Rodman & Renshaw Royal Bank of Canada Sectoral Asset Management SG Cowen Siparex Sofinnova Soyco Capital Management Swiss Re Swissfirst Bank Swiss National Bank SWX Talentmark ThinkEquity Tilocor International S.A. Truffle Venture Turenne Capital TVM UBS Unicorn Bio Tutors Union Bancaire Privée Venture Incubator VI Partners AG Vinci Capital Vision Capital WestLB Panmure Widmann Associates Wolf Research & Asset Mgt |